Genetic toxicology in the 21st century: Reflections and future directions

Merck Research Laboratories, Genetic Toxicology, Mechanistic and Predictive Toxicology, Summit, New Jersey, USA.
Environmental and Molecular Mutagenesis (Impact Factor: 2.63). 06/2011; 52(5):339-54. DOI: 10.1002/em.20653
Source: PubMed


A symposium at the 40th anniversary of the Environmental Mutagen Society, held from October 24-28, 2009 in St. Louis, MO, surveyed the current status and future directions of genetic toxicology. This article summarizes the presentations and provides a perspective on the future. An abbreviated history is presented, highlighting the current standard battery of genotoxicity assays and persistent challenges. Application of computational toxicology to safety testing within a regulatory setting is discussed as a means for reducing the need for animal testing and human clinical trials, and current approaches and applications of in silico genotoxicity screening approaches across the pharmaceutical industry were surveyed and are reported here. The expanded use of toxicogenomics to illuminate mechanisms and bridge genotoxicity and carcinogenicity, and new public efforts to use high-throughput screening technologies to address lack of toxicity evaluation for the backlog of thousands of industrial chemicals in the environment are detailed. The Tox21 project involves coordinated efforts of four U.S. Government regulatory/research entities to use new and innovative assays to characterize key steps in toxicity pathways, including genotoxic and nongenotoxic mechanisms for carcinogenesis. Progress to date, highlighting preliminary test results from the National Toxicology Program is summarized. Finally, an overview is presented of ToxCast™, a related research program of the U.S. Environmental Protection Agency, using a broad array of high throughput and high content technologies for toxicity profiling of environmental chemicals, and computational toxicology modeling. Progress and challenges, including the pressing need to incorporate metabolic activation capability, are summarized.

Download full-text


Available from: Ronald Snyder,
  • Source
    • "Although this is not directly relevant to the current study, as in vitro endpoints are rarely acknowledged to represent adverse endpoints, there is certainly evidence that effects observed in in vitro studies are relevant to in vivo endpoints (see for example (Wang et al., 2012)), and there have been strong recommendations that results from in vitro studies be considered relevant to effects that are likely to be observed at other levels of biological organization (Schug et al., 2013). Furthermore, the development of Tox21, ToxCast, and other high throughput in vitro assays acknowledges that in vitro cell based assays and cell-free assays provide important tools that can and should inform chemical risk assessments (Knudsen et al., 2013; Mahadevan et al., 2011). These assays have many benefits over in vivo tests, including the ability to test large numbers of doses over a large span of log concentrations, their high sensitivity and specificity, and their use of state-of-the-art techniques (Shukla et al., 2010; Sun et al., 2012). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Non-monotonic dose response curves (NMDRCs) have been demonstrated for natural hormones and endocrine disrupting chemicals (EDCs) in a variety of biological systems including cultured cells, whole organ cultures, laboratory animals and human populations. The mechanisms responsible for these NMDRCs are well known, typically related to the interactions between the ligand (hormone or EDC) and a hormone receptor. Although there are hundreds of examples of NMDRCs in the EDC literature, there are claims that they are not 'common enough' to influence the use of high-to-low dose extrapolations in risk assessments. Here, we chose bisphenol A (BPA), a well-studied EDC, to assess the frequency of non-monotonic responses. Our results indicate that NMDRCs are common in the BPA literature, occurring in greater than 20% of all experiments and in at least one endpoint in more than 30% of all studies we examined. We also analyzed the types of endpoints that produce NMDRCs in vitro and factors related to study design that influence the ability to detect these kinds of responses. Taken together, these results provide strong evidence for NMDRCs in the EDC literature, specifically for BPA, and question the current risk assessment practice where 'safe' low doses are predicted from high dose exposures.
    Dose-Response 05/2014; 12(2):259-76. DOI:10.2203/dose-response.13-020.Vandenberg · 1.22 Impact Factor
  • Source
    • "The aerosol is created by gentle and controlled heating of the tobacco, which yields a smoke aerosol composed primarily of water and a humectant, for example glycerol, with reduced concentrations of combustion-related constituents such as aldehydes and polycyclic aromatic hydrocarbons. Systems toxicology concepts such as the ''21st Century Toxicology'' (Mahadevan et al., 2011; Stephens et al., 2012) have recently been suggested to augment current toxicological risk assessment and to facilitate an understanding of the molecular mechanisms underlying the impact of biologically active substances/toxicants and associated disease risks. With a view to developing a systems toxicology-based product risk assessment approach, the aims of this study were to: (a) demonstrate that the correlative evaluation of histopathology with gene expression analysis and advanced modeling tools is feasible within a classical Organization for Economic Co-operation and Development (OECD) inhalation study and can provide additional details about the molecular mechanisms underlying the test substance-related morphological changes, and (b) demonstrate reduced exposure effects for a single high dose of pMRTP compared with a conventional reference cigarette using this combined approach. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Towards a systems toxicology-based risk assessment, we investigated molecular perturbations accompanying histopathological changes in a 28-day rat inhalation study combining transcriptomics with classical histopathology. We demonstrated reduced biological activity of a prototypic modified risk tobacco product (pMRTP) compared with the reference research cigarette 3R4F. Rats were exposed to filtered air or to three concentrations of mainstream smoke (MS) from 3R4F, or to a high concentration of MS from a pMRTP. Histopathology revealed concentration-dependent changes in response to 3R4F that were irritative stress-related in nasal and bronchial epithelium, and inflammation-related in the lung parenchyma. For pMRTP, significant changes were seen in the nasal epithelium only. Transcriptomics data were obtained from nasal and bronchial epithelium and lung parenchyma. Concentration-dependent gene expression changes were observed following 3R4F exposure, with much smaller changes for pMRTP. A computational-modeling approach based on causal models of tissue-specific biological networks identified cell stress, inflammation, proliferation, and senescence as the most perturbed molecular mechanisms. These perturbations correlated with histopathological observations. Only weak perturbations were observed for pMRTP. In conclusion, a correlative evaluation of classical histopathology together with gene expression-based computational network models may facilitate a systems toxicology-based risk assessment, as shown for a pMRTP.
    Food and chemical toxicology: an international journal published for the British Industrial Biological Research Association 03/2014; 68. DOI:10.1016/j.fct.2014.02.034 · 2.90 Impact Factor
  • Source
    • "As most laboratory studies evaluated the tumorigenic dose, there is a compelling need for data at subtumorigenic doses to understand the molecular and mechanistic events and the sexspecific differences involved in CAR-mediated hepatotumorigenesis . Further, newer molecular technologies such as wholegenome transcriptional analysis now complement conventional bioassay endpoints such as histopathology, enzyme activity, and biochemical assays (Mahadevan et al., 2011; Waters and Yauk, 2007). Similarly, benchmark dose (BMD) response methods have been employed since the 1980s to aid in low-dose quantitative risk assessment (Crump, 1984), and these methods have since been adapted for microarray data and combined genelevel BMD estimates to facilitate mapping to cellular pathways (Thomas et al., 2007, 2013; Yang et al., 2007). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Low-dose extrapolation and dose-related transitions are paramount in the ongoing debate regarding the quantification of cancer risks for non-genotoxic carcinogens. Phenobarbital (PB) is a prototypical non-genotoxic carcinogen that activates the constitutive androstane receptor (CAR) resulting in rodent liver tumors. In this study, male and female CD-1 mice administered dietary PB at 0, 0.15, 1.5, 15, 75, or 150 mg/kg-day for 2 or 7 days to characterize multiple apical and molecular endpoints below, at (∼75 mg/kg-day), and above the carcinogenic dose level of PB and examine these responses using benchmark dose modeling. Linear toxicokinetics were observed for all doses. Increased liver weight, hepatocellular hypertrophy, and mitotic figures were seen at 75 and 150 mg/kg-day. CAR activation, based on Cyp2b qPCR and pentoxyresorufin dealkylase activity, occurred at doses ≥ 1.5 mg/kg-day. The no-observable transcriptional effect level for global gene expression was 15 mg/kg-day. At 2 days, several xenobiotic metabolism and cell protective pathways were activated at lower doses and to a greater degree in females. However, hepatocellular proliferation, quantified by BrdU immunohistochemistry, was the most sensitive indicator of PB exposure with female mice more sensitive than males, contrary to sex-specific differences in sensitivity to hepatocarcinogenesis. Taken together, the identification of low-dose cellular and molecular transitions in the subtumorigenic dose range aids the understanding of early key events in CAR-mediated hepatocarcinogenesis.
    Toxicological Sciences 01/2014; 138(2). DOI:10.1093/toxsci/kfu014 · 3.85 Impact Factor
Show more